Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "NCEs"

2811 News Found

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia
News | March 03, 2026

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia

Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications


Zydus receives final approvals from USFDA for Ivermectin Tablets USP
Drug Approval | March 02, 2026

Zydus receives final approvals from USFDA for Ivermectin Tablets USP

Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans


IRLAB Therapeutics doses first patient in pivotal apathy trial
Clinical Trials | March 02, 2026

IRLAB Therapeutics doses first patient in pivotal apathy trial

The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain


SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026
Digitisation | March 02, 2026

SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026

During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions


Novo Nordisk invests €432 million to expand Athlone facility for global Wegovy pill supply
News | March 02, 2026

Novo Nordisk invests €432 million to expand Athlone facility for global Wegovy pill supply

The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202


Zydus hits Keytruda biosimilar milestone with successful FYB206 trial, targets USFDA filing
News | February 28, 2026

Zydus hits Keytruda biosimilar milestone with successful FYB206 trial, targets USFDA filing

Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets


Thermo Fisher launches genetic test to personalize transplant drug dosing
Technology | February 28, 2026

Thermo Fisher launches genetic test to personalize transplant drug dosing

The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus


Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial
Clinical Trials | February 28, 2026

Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial

The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints


Zydus to disrupt GLP-1 market with day-1 launch of innovative Semaglutide in India
News | February 26, 2026

Zydus to disrupt GLP-1 market with day-1 launch of innovative Semaglutide in India

Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights


Volta Labs unveils push-button PCR-free whole genome sequencing kit
News | February 26, 2026

Volta Labs unveils push-button PCR-free whole genome sequencing kit

The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform